Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model

Liu, Jia; He, Xiaoning; Wu, Jing

doi:10.1007/s40258-022-00732-1

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cost for exacerbations was calculated from the results of a cross-sectional study was carried out among 678 COPD patients in four cities in China in 2011, 31 including outpatient visit for non-severe exacerbations and hospital admission for severe exacerbations. The AEs treatment costs were obtained from previous research, 30 including treatment costs for pneumonia, nasopharyngitis, bronchitis, dysphonia, and upper respiratory tract infection.…”

Section: Methodsmentioning

confidence: 99%

“…Severe exacerbation in GOLD II 1165.52 [31] Severe exacerbation in GOLD III 1491.69 [31] Severe exacerbation in GOLD IV 1992.06 [31] Non-severe exacerbation in GOLD II 84.87 [31] Non-severe exacerbation in GOLD III 88.53 [31] Non-severe exacerbation in GOLD IV 135.28 [31] AEs treatment costs Pneumonia 436.26 [30] Nasopharyngi 14.54 [30] Bronchitis 14.54 [30] Upper respiratory tract infection 7.27 [30] Abbreviations: FDC, fixed-dose combination; GOLD II, moderate COPD; GOLD III, severe COPD; GOLD IV, very severe COPD; TIO, tiotropium bromide; TIO/OLO, tiotropium bromide/olodaterol; AEs, adverse events.…”

Section: Costs Of Exacerbationsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China

Lan,

Yang,

Wang

et al. 2023

COPD

View full text Add to dashboard Cite

Tiotropium/olodaterol (TIO/OLO) fixed-dose combination (FDC) can improve lung function and quality of life for patients with chronic obstructive pulmonary disease (COPD), and is not inferior to other LAMA/LABAs. The aim of this study was to assess the cost-effectiveness of TIO/OLO FDC in patients with moderate to very severe COPD in China. Methods: A Markov model was developed to estimate the cost-effectiveness of TIO/OLO FDC versus TIO in the treatment of COPD from Chinese health system perspective. Four health states were based on 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD 2021), which included moderate (GOLD II, 50% ≤ FEV1 ≤ 80% of predicted), severe (GOLD III, 30% ≤ FEV1 ≤ 50% of predicted) and very severe (GOLD IV, FEV1 > 30% of predicted) COPD and death. The model simulated in cycles yearly. The indicators of total costs, number of COPD exacerbations, life years (LYs) and quality-adjusted life-years (QALYs) were used as the model output. Costs and outcomes were discounted at a 5% annual rate. A cost-effectiveness analysis was conducted over a 10-year time horizon. The threshold of incremental total cost per unit effectiveness gained (ICER) was 1.5 times of GDP per capita. Uncertainty was assessed by one-way and probabilistic sensitivity analysis. Results: TIO/OLO was 0.007 QALYs more than TIO but 0.012 LYs lower, which increased the total cost by $2268.17 per patient, but the total exacerbations number was less. Incremental cost effectiveness analysis had shown that the ICER exceeded the willingness to pay threshold. Results were robust under most parameter variation, except the parameters of total drug cost of TIO/OLO FDC in univariate sensitivity analyses. Conclusion: Although TIO/OLO FDC could reduce the exacerbation risk, it was not cost-effective, and needed to be repriced.

show abstract

Section: Methodsmentioning

confidence: 99%